Board of Directors

Steven Gillis, Ph.D., Executive Chairman
Managing Director, ARCH Venture Partners

Dr. Gillis has been a member of Allozyne’s board of directors since October 2007. Since 2005, Mr. Gillis has been a Managing Director at ARCH Venture Partners, where he focuses on the evaluation of new life science technologies and also on the development and growth of ARCH’s biotechnology portfolio companies. Dr. Gillis served as Trubion Pharmaceuticals’ Executive Chairman, Acting President and Chairman of the Board from November 2009 until Trubion’s acquisition in October 2010 and as a director from 2006 until Trubion’s acquisition. Dr. Gillis was a founder and director of Corixa Corporation, a biotechnology company that was acquired by GlaxoSmithKline in July 2005. Dr. Gillis served as Corixa’s Chief Executive Officer from 1994 to July 2005 and as its Chairman of the Board from January 1999 to July 2005. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corporation, a biotechnology company that was subsequently acquired by Amgen Inc. in 2002. While at Immunex, Dr. Gillis served as Immunex’s interim Chief Executive Officer and a member of the board of directors, Immunex’s Director of Research and Development, Chief Scientific Officer, and Chief Executive Officer of Immunex’s Research and Development subsidiary. Dr. Gillis is an immunologist by training and is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products, including Leukine®, Prokine®, Enbrel®, and Bexxar®. Dr. Gillis received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth College in 1978. Dr. Gillis’ qualifications to sit on the board of the combined company include his more than 30 years of experience in the life science industry, his founding of multiple successful biotechnology companies, and his experience serving in the chairman or executive chairman role.

Michael Steinmetz, Ph.D.
Managing Director, Clarus Ventures/ MPM BV III

Dr. Steinmetz has been Allozyne’s Executive Chairman of the board of directors since October 2007. Dr. Steinmetz serves as Affiliate Managing Director of MPM’s BioVentures Funds I to III. He also holds positions on the boards of Heptares Therapeutics, Oxford Immunotech, Inc., Macrogenics, Inc., TaiGen Biotechnology Co., Ltd., Tetralogic Pharmaceuticals, and Virdante Pharmaceuticals, Inc. Since December 2005, Dr. Steinmetz has been the Managing Director at Clarus Ventures, a venture capital firm with offices in Boston and San Francisco, focused on investments in biotechnology, specialty pharma and medical device companies in the United States and Europe. Prior to Clarus Ventures, Dr. Steinmetz was General Partner at MPM Capital from 1997 to 2005, where he helped establish the BioVentures family of funds. From 1986 to 1997, Dr. Steinmetz was an executive at F. Hoffmann-LaRoche Ltd., where he held various positions, including Vice President of Preclinical Research and Development and Global Head of Biotechnology. Dr. Steinmetz has held academic positions at the University of Munich, the California Institute of Technology and the Basel Institute for Immunology. He received his scientific training in chemistry, molecular biology and immunology. As an active participant in the medical device industry, Dr. Steinmetz brings to the board a diversity of management, operational, and product development experience.

Carl Weissman
Managing Director, OVP Venture Partners

Mr. Weissman has been a member of Allozyne’s board of directors since November 2004. Since March 2003, Mr. Weissman has been the Chairman and Chief Executive Officer of Accelerator Corporation. Since January 2009, Mr. Weissman has been a Managing Director of OVP Venture Partners, focusing particularly on the operational aspects of OVP portfolio companies. At Accelerator, Mr. Weissman has led Accelerator-based investment in five companies, securing approximately $148.1 million in capital commitments from Accelerator investors MPM Capital, Amgen Ventures, OVP Venture Partners, ARCH Venture Partners, Versant Ventures, and Alexandria Real Estate Equities. Prior to that, Mr. Weissman was a Venture Partner at MPM Capital, where he served as the President and Chief Executive Officer of Centagenetix, led the merger of Centagenetix with Elixir Pharmaceuticals, Inc., and remained on the board of directors of the combined entity until January 2005. Prior to joining MPM Capital, Mr. Weissman spent six years at Prolinx, Inc., where he held a number of positions, culminating as the head of both Finance and Business Development. Mr. Weissman brings to the board expertise in the areas of business strategy, financial management, operations and equity finance.

David Tirrell, Ph.D.
Ross McCollum-William H. Corcoran Professor and Professor of Chemistry and Chemical Engineering
Chair, Division of Chemistry and Chemical Engineering, California Institute of Technology
Co-Founder, ALLOZYNE

Dr. Tirrell received his B.S. and Ph.D. degrees from MIT and the University of Massachusetts, respectively. Dr. Tirrell was an assistant professor in the Department of Chemistry at Carnegie-Mellon University, and then returned to the University of Massachusetts as the Director of the Materials Research Laboratory and Barrett Professor of Polymer Science and Engineering. Dr. Tirrell currently serves as Division Chair for Chemistry and Chemical Engineering at Caltech. He is a Fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. Dr. Tirrell was Editor of the Journal of Polymer Science, Part A: Polymer Chemistry, and has served on the editorial boards of Macromolecules, ChemBioChem, Accounts of Chemical Research, Chemical and Engineering News, and several other journals. Dr. Tirrell chaired the 1994 Gordon Research Conference on Polymers in Biosystems and the 1995 Gordon Conference on Chemistry of Supramolecules and Assemblies.

Meenu Chhabra Karson
President & Chief Executive Officer, ALLOZYNE

Ms. Chhabra Karson has been Allozyne’s President and Chief Executive Officer since September 2007 and Allozyne’s director since October 2007. Prior to Allozyne, she served as Vice President of Business Development and Licensing for Novartis (Switzerland) from November 2006 to August 2007. While at Novartis, she specialized in leading and executing merger and acquisition transactions in emerging markets. Before joining Novartis, she served as Chief Business Officer at BioXell SpA, a spin-off from F. Hoffmann-LaRoche Ltd.’s Milan Research Institute (Italy) from September 2003 to October 2006, where she led corporate development and financing activities, which culminated in a series of transactions with top-tier pharmaceutical companies including Merck & Co., Inc., and F. Hoffman-LaRoche Ltd. Ms. Chhabra Karson has also held management positions with Fresenius Kabi AG, Warner Lambert, Inc., and Bristol-Myers Squibb, Inc. She obtained her M.B.A. from York University and her B.Sc. from the University of Toronto. Ms. Chhabra Karson brings to the board a deep familiarity with Allozyne’s operations, strategy and vision and a strong record of successful corporate and product portfolio planning and management.